Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Mexico: Swine flu toll stabilizing Cuba and Argentina impose travel bans as virus continues to spread msnbc.com staff and news service reports updated 11:48 p.m. ET April 28, 2009 The toll from the swine flu epidemic appears to be stabilizing in Mexico, the health secretary said late Tuesday, with only seven more suspected deaths. But an outbreak of the virus at a New York school showed it is capable of repeated jumps between humans — meaning it can keep spreading around the world. The new virus is suspected in 159 deaths and 2,498 illnesses across Mexico, said Health Secretary Jose Cordova, who called the death toll "more or less stable" even as hospitals are swamped with people who think they have swine flu. And he said only 1,311 suspected swine flu patients remain hospitalized, a sign that treatment works for people who get medical care quickly. The positive news came even as the first two countries announced travel bans on flights from Mexico, the center of the epidemic, and as confirmed cases were reported for the first time as far away as New Zealand and Israel, joining the United States, Canada, Britain and Spain. Dirk
Griepvaccins gevaarlijker dan varkensgriep zelf In het onderstaande filmpje reageert congresman Dr. Ron Paul op de overdreven reactie van de overheid op de varkensgriep. In 1976, toen er een zelfde soort griep werd geconstateerd, bezweek er maar liefst één persoon aan het griepvirus zelf, terwijl er 25 anderen overleden aan de gevolgen van de vaccinaties die er tegen werden verstrekt. Vele anderen werden behoorlijk ziek na te zijn ingeënt. Het aantal doden nu blijft beperkt en zijn alleen geteld in Mexico. Verder zijn geen mensen met ernstige klachten opgenomen in ziekenhuizen. Meer dan 13.000 gevallen van TBC zijn bekend in het afgelopen jaar. Hiermee kun je spreken van een ernstige ziekte en valt het varkensgriepvirus totaal in het niet. De overheid is in samenwerking met Homeland Security onnodig aan het paniekzaaien, terwijl die zich in feite niet eens zouden moeten bemoeien met de medische zorg, zegt Paul.www.youtube.com/watch?v=TB5-Y08qbjo de fase I aankondiging van CRXL heeft dus eigenlijk meer waarde dan de varkensgriepperikelen....?
invoorentegenspoed schreef:
de fase I aankondiging van CRXL heeft dus eigenlijk meer waarde dan de varkensgriepperikelen....?
Moest het reizigers direct bedreigen, dan wel !
"Es ist richtige Sweinerei ..." First researchers had to grow enough virus samples, culled from a handful of patients, to work with. Influenza virus traditionally is grown by injecting it into fertilized chicken eggs, but this novel virus didn't grow easily there. There's an alternative, growing it in vats of cells instead, but most flu vaccine manufacturers today still rely on eggs. "There is a little bit of concern there," said CDC's Donis, whose laboratory eventually created three samples that did grow in eggs, just slowly. More work is under way to try to improve that." (From yahoo forum). De oplossing: experimenteerlabo PERCIVIA 'Do it yourself...'
aossa schreef:
"There is a little bit of concern there," said CDC's Donis, whose laboratory eventually created three samples that did grow in eggs, just slowly. More work is under way to try to improve that."
CDC's Donis …en deze meneer is weer verbonden met Marasco’s “van die andere” antibodies-groep:www.ncbi.nlm.nih.gov/pubmed/19234466
Half miljoen voor onderzoek nieuw griepmedicijn 29 april 2009, 15:58 | ANP UTRECHT (ANP) - Onderzoekers van het Erasmus MC in Rotterdam en de Universiteit Utrecht hebben ruim een half miljoen euro subsidie gekregen voor onderzoek naar nieuwe preventieve medicijnen tegen griepvirussen. Dat hebben ze woensdag bekendgemaakt. Het geld is afkomstig van technologiestichting STW. Volgens een woordvoerder van de Universiteit Utrecht zat het geld er al langer aan te komen en is het toeval dat de toekenning samenvalt met de dreiging van het Mexicaanse varkensgriepvirus. Het onderzoek begint in juli en zal enkele jaren duren. De onderzoekers hopen dat het helpt om bij volgende uitbraken de kracht van de virussen te beperken. De medicijnen zullen geen vervangers worden van de griepvacccins.
Nederlanders blijven nuchter onder griepdreiging 29 april 2009, 15:55 | ANP RIJSWIJK (ANP) - Nederland blijft nog steeds nuchter onder de dreiging van de varkensgriep. Apotheken, artsen en GGD ontvangen maar weinig bezorgde telefoontjes over de mogelijke dreiging van de ziekte. Dat blijkt uit een rondgang langs een groot aantal apotheken, artsen en GGD's in de grote steden. De GGD in Amsterdam kreeg de afgelopen dagen tussen dertig en vijftig extra telefoontjes per dag, wat representatief is voor alle grote steden. ,,Mensen bellen met algemene vragen over de varkensgriep, ze zijn bijvoorbeeld bezorgd over een geplande reis naar Mexico of over familie die uit Mexico overkomt'', stelt een woordvoerder. ,,Anderen vragen welke voorzorgsmaatregelen ze thuis kunnen nemen. Maar van paniek is geen sprake.'' Volgens vicepremier André Rouvoet is Nederland goed voorbereid op een eventuele verspreiding van het virus naar ons land. Dat zei hij, nadat hij de wekelijkse ministerraad had voorgezeten. ,,We houden de vinger nauwgezet aan de pols. Er is geen reden voor paniek. Wel is alertheid en waakzaamheid nodig.'' Rouvoet erkende dat een wereldwijde verspreiding van een griepvirus uiteraard altijd onzekerheden met zich brengt. Volgens hem zijn echter alle draaiboeken over wie wanneer actie moet ondernemen op orde en worden zaken internationaal goed afgestemd. Ook wees hij erop dat deskundigen zeggen dat ons land met 4,5 miljoen doses aan antivirale middelen voldoende voorraad heeft.
- Sanofi-aventis and its vaccines division Sanofi Pasteur pursue pandemic preparedness plan in response to WHO Phase 4 influenza pandemic alert - Paris, France – 29 April 2009 – Sanofi-aventis (EURONEXT : SAN and NYSE : SNY) and its vaccines division Sanofi Pasteur announce today their readiness to support public health efforts to prevent the circulation of a new influenza A/H1N1 virus following the decision made by the World Health Organization (WHO) to raise the influenza pandemic alert level from phase 3 pandemic preparedness to phase 4. The change to a higher phase of pandemic alert indicates that the likelihood of a pandemic has increased. This decision triggers the next steps in sanofi-aventis Group pandemic preparedness plans. Sanofi Pasteur, as the world's leading producer of influenza vaccine, will continue to manufacture seasonal influenza vaccine as recommended by the WHO on April 27, 2009. It will also stand ready to develop a vaccine effective against the new A /H1N1 virus identified by the WHO. Sanofi-aventis has been contacted by health and regulatory authorities regarding the development and production of a vaccine that would help prevent the spread of this new influenza A/H1N1 virus, once a vaccine strain is available from health authorities. Sanofi Pasteur continues to monitor the situation regarding the emergence of this new influenza A/H1N1 virus and to support efforts led by the WHO, the Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC) in the United States, the Government of Mexico, the European Centre for Disease Prevention and Control (ECDC) and various other health authorities around the world. The decision to raise the level of pandemic preparedness to phase 4 was based primarily on epidemiological data demonstrating human-to-human transmission and the ability of the virus to cause community-level outbreaks, according to the WHO. Phase 4 indicates a significant increase in risk of a pandemic but does not necessarily mean that a pandemic is inevitable. Pandemic preparedness Sanofi-aventis is actively involved in pandemic preparedness and has invested in a major expansion of its influenza vaccine production capacity. Sanofi Pasteur is also committed to continuing its robust research and development program by exploring strategies for protecting more people.en.sanofi-aventis.com/binaries/200904... Sanofi en Novartis aangezocht voor griepvaccin • woensdag 29 april 2009 • Bron: afp/belga • Auteur: dsl PARIJS - Het Franse farmaceutische bedrijf Sanofi Pasteur en het Zwitserse Novartis zijn door de Wereldgezondheidsorganisatie (WHO) gevraagd om een vaccin te ontwikkelen tegen de Mexicaanse griep. Dat meldt Sanofi woensdag in een mededeling. Zodra het virus is geïdentificeerd, kan Sanofi naar eigen zeggen starten met de productie van het vaccin. Het laboratorium staat in contact met de Amerikaanse Food and Drug Administration (FDA) en het European Medicines Agency (EMEA), die hun toelating moeten geven voor de aanmaak van het vaccin. Ook het Zwitserse Novartis werd deze week benaderd door de WHO. Farmareus Roche beschikt intussen over 3 miljoen dosissen Tamiflu, een van de twee geneesmiddelen die door de Gezondheidsorganisatie worden aanbevolen voor de behandeling van de Mexicaanse griep. Het Britse GlaxoSmithKline heeft 100.000 doosjes Relenza, het andere geneesmiddel, bezorgd aan Mexico en zoekt naar mogelijkheden om de productie te verhogen.www.standaard.be/Artikel/Detail.aspx?...
Dode varkensgriep VS was Mexicaanse 29 april 2009, 16:19 | ANP WASHINGTON (ANP) - De peuter die in de Verenigde Staten bezweek aan varkensgriep, kwam uit Mexico. De ouders brachten het kind naar een ziekenhuis in de stad Houston in Texas voor behandeling. Vergeefs, want het overleed daar. Dat meldde de nieuwszender CNN woensdag. Het gaat om het eerste sterfgeval door de ziekte buiten Mexico. De staat Texas grenst aan dat land. In Mexico zijn officieel bijna 2500 mensen besmet. Zeker zeven mensen zijn daar overleden aan de ziekte. De meeste patiënten hebben slechts milde symptomen van de varkensgriep.
Arts moet naam besmet persoon registreren 29 april 2009, 16:27 | ANP DEN HAAG (ANP) - Medici moeten mensen die besmet zijn met de varkensgriep op naam registreren. Minister Ab Klink (Volksgezondheid) heeft deze aangifteplicht woensdag aangekondigd. Familieleden en andere omstanders van mensen die zijn besmet met het griepvirus, zullen volgens hem het preventieve medicijn Tamiflu krijgen. Klink, die steevast over de Mexicaanse griep spreekt, benadrukte dat er in Nederland geen redenen zijn voor grote bezorgdheid. Er zijn hier nog geen gevallen van besmetting bekend. ,,Maar we zijn wel superalert'', zei de minister. Tot nu toe gold de regel dat mensen die met het virus zijn besmet, op regionaal of plaatselijk niveau worden geregistreerd. Klink heeft ervoor gekozen dat dat nu ,,op naamsniveau'' moet gebeuren.
voda schreef:
Arts moet naam besmet persoon registreren
29 april 2009, 16:27 | ANP
DEN HAAG (ANP) - Medici moeten mensen die besmet zijn met de varkensgriep op naam registreren. Minister Ab Klink (Volksgezondheid) heeft deze aangifteplicht woensdag aangekondigd.
......en een lintje voor z'n moeder.www.minvws.nl/nieuwsberichten/staf/20...
Dit is het online spel The Great Flu(www.thegreatflu.com). De speler is de leider van een internationale gezondheidsorganisatie die een dreigende griepepidemie moet stoppen. Het begint meteen al met ronkend filmpje: Jaws-achtig muziekje, archiefbeeld van de Spaanse griep uit 1918 die 20 tot 100 miljoen doden opleverde, Aziaten met mondkapjes. ‘Het lot van de wereld ligt in jouw handen!’
flosz schreef:
[quote=flosz]
CDC-teller staat nog op 40.
www.cdc.gov/swineflu/ [/quote]
Hoppa, 64 nu.
91 cases 1 death
Zonder griep krimpt Mexicaanse economie al flink 29 april 2009, 20:38 | ANP MEXICO-STAD (AFN) - De Mexicaanse economie zal dit jaar naar verwachting tussen de 3,8 procent en 4,8 procent krimpen als gevolg van de wereldwijde economische teruggang. Dat gaf de Mexicaanse centrale bank woensdag aan. Daar moet bij aangetekend worden dat de voorspelling is gebaseerd op data die zijn verzameld voordat het land getroffen werd door varkensgriep. De verwachting is dan ook dat een volgende voorspelling van de centrale bank slechter zal zijn door de gevolgen voor de economie van de uitbraak van het griepvirus, dat in Mexico al meer dan 150 dodelijke slachtoffers zou hebben gemaakt. Alle eetgelegenheden, sportclubs en culturele instellingen in Mexico zijn gesloten om verdere verspreiding van het virus te voorkomen. Bovendien reizen minder mensen naar Mexico, wat zijn impact heeft op de grote toeristische industrie.
Swine flu: The predictable pandemic? 29 April 2009 by Debora MacKenzie THE swine flu virus has been a serious pandemic threat for years, New Scientist can reveal - but research into its potential has been neglected compared with other kinds of flu. As New Scientist went to press, cases were being reported far from the original outbreak in Mexico. The clusters of milder infections in the US suggest the virus is spreading readily among people. The US Centers for Disease Control and Prevention (CDC) says this strain is so different from existing human flu viruses that most people have no immunity to it. There are no existing vaccines. All this means the virus could go pandemic. Or it might not: if the virus spreads less readily than is feared, it might not be able to maintain itself in the human population and could fizzle out (see "What makes flu go global?"). We could have seen this coming, though. This type of virus emerged in the US in 1998 and has since become endemic on hog farms across North America. Equipped with a suite of pig, bird and human genes, it was also evolving rapidly. Flu infects many animals, including waterfowl, pigs and humans. Birds and people rarely catch flu viruses adapted to another host, but they can pass flu to pigs, which also have their own strains.If a pig catches two kinds of flu at once it can act as a mixing vessel, and hybrids can emerge with genes from both viruses. This is what happened in the US in 1998. Until then, American pigs had regular winter flu, much like people, caused by a mutated virus from the great human pandemic of 1918, which killed pigs as well as at least 50 million people worldwide. This virus was a member of the H1N1 family - with H and N being the virus's surface proteins haemagglutinin and neuraminidase. Over decades, H1N1 evolved in pigs into a mild, purely swine flu, and became genetically fairly stable. In 1976, there was an outbreak of swine H1N1 in people at a military camp in New Jersey, with one death. The virus did not spread efficiently, though, and soon fizzled out. But in 1998, says Richard Webby of St Jude's Children's Research Hospital in Memphis, Tennessee, swine H1N1 hybridised with human and bird viruses, resulting in "triple reassortants" that surfaced in Minnesota, Iowa and Texas. The viruses initially had human surface proteins and swine internal proteins, with the exception of three genes that make RNA polymerase, the crucial enzyme the virus uses to replicate in its host. Two were from bird flu and one from human flu. Researchers believe that the bird polymerase allows the virus to replicate faster than those with the human or swine versions, making it more virulent. By 1999, these viruses comprised the dominant flu strain in North American pigs and, unlike the swine virus they replaced, they were actively evolving. There are many versions with different pig or human surface proteins, including one, like the Mexican flu spreading now, with H1 and N1 from the original swine virus. All these viruses still contained the same "cassette" of internal genes, including the avian and human polymerase genes, reports Amy Vincent of the US Department of Agriculture (USDA) in Ames, Iowa (Advances in Virus Research, vol 72, p 127). "They are why the swine versions of this virus easily outcompete those that don't have them," says Webby. But the viruses have been actively switching surface proteins to evade the pigs' immunity. There are now so many kinds of pig flu that it is no longer seasonal. One in five US pig producers actually makes their own vaccines, says Vincent, as the vaccine industry cannot keep up with the changes. This rapid evolution posed the "potential for pandemic influenza emergence in North America", Vincent said last year. Webby, too, warned in 2004 that pigs in the US are "an increasingly important reservoir of viruses with human pandemic potential". One in five US pig workers has been found to have antibodies to swine flu, showing they have been infected, but most people have no immunity to these viruses. The virus's rapid evolution created the potential for a pandemic to emerge in North America Our immune response to flu, which makes the difference between mild and potentially lethal disease, is mainly to the H surface protein. The Mexican virus carries the swine version, so the antibodies we carry to human H1N1 viruses will not recognise it. That's why the CDC warned last year that swine H1N1 would "represent a pandemic threat" if it started circulating in humans. The avian polymerase genes are especially worrying, as similar genes are what make H5N1 bird flu lethal in mammals and what made the 1918 human pandemic virus so lethal in people. "We can't yet tell what impact they will have on pathogenicity in humans," says Webby. It appears the threat has now resulted in the Mexican flu. "The triple reassortant in pigs seems to be the precursor," Robert Webster, also at St Jude's, told New Scientist. While researchers focused on livestock problems could see the threat developing, it is not one that medical researchers focused on human flu viruses seemed to have been aware of. "It was confusing when we looked up the gene sequences in the database," says Wendy Barclay of Imperial College London, who has been studying swine flu from the recent US cases. "The polymerase gene sequences are bird and human, yet they were reported in viruses from pigs." So where did the Mexican virus originate? The Veratect Corporation based in Kirkland, Washington, monitors world press and government reports to provide early disease warnings for clients, including the CDC. Their first inkling of the disease was a 2 April report of a surge in respiratory disease in a town called La Gloria, east of Mexico City, which resulted in the deaths of three young children. Only on 16 April - after Easter week, when millions of Mexicans travel to visit relatives - reports surfaced elsewhere in the country. Local reports in La Gloria blamed pig farms in nearby Perote owned by Granjas Carroll, a subsidiary of US hog giant Smithfield Foods. The farms produce nearly a million pigs a year. Smithfield Foods, in a statement, insists there are "no clinical signs or symptoms" of swine flu in its pigs or workers in Mexico. That is unsurprising, as the company says it "routinely administers influenza virus vaccination to swine herds and conducts monthly tests for the presence of swine influenza." The company would not tell New Scientist any more about recent tests. USDA researchers say that while vaccination keeps pigs from getting sick, it does not block infection or shedding of the virus. All the evidence suggests that swine flu was a disaster waiting to happen. But it got little research attention, perhaps because it caused mild infections in people which didn't spread. Now one swine flu virus has stopped being so well-behaved. What makes flu go global? A "pandemic" is an epidemic that goes global, so technically there is a flu pandemic every year. But the term is usually reserved for bad outbreaks that follow large changes in the virus. The influenza virus constantly evolves, and pandemics happen every few decades when the flu virus gets new surface proteins that people have little immunity to, generally because they come from an animal strain. The lack of immunity means the virus affects more people more severely. That's why H5N1 bird flu
Level 5 wordt zo aangekondigd. Bron: Bloomberg
RIVM hanteert term Mexicaanse griep 29 april 2009, 21:58 | ANP BILTHOVEN (ANP) - Het Rijksinstituut voor Volksgezondheid en Milieu (RIVM) hanteert vanaf woensdag de term Mexicaanse griep in plaats van varkensgriep. Dat heeft een woordvoerder laten weten. De verandering is ingegeven door een beslissing van het zogeheten Outbreak Management Team, een groep van deskundigen die woensdag over de griep vergaderde. Het RIVM is lid van deze adviesgroep. De term Mexicaanse griep past volgens de zegsman beter in het rijtje namen van eerdere griepsoorten als Hong Kong griep en Spaanse griep. Varkensgriep was al geen adequate term, omdat het gaat om een menselijk griepvirus, dat bestaat uit een mengsel van het 'gewone' griepvirus, het vogelgriepvirus en het varkensgriepvirus.
How to survive a potential killer 29 April 2009 by Debora MacKenzie THERE are three approaches to an infectious disease: you can survive it (or not), kill off the bug responsible, or best of all prevent it. If swine flu goes pandemic, what should we do? First, there's treating it. The Mexican swine flu resists older antiviral drugs like rimantadine. It is still susceptible to the Tamiflu and Relenza in national stockpiles - such as they are - but virologists were shocked this past flu season when ordinary human H1N1 spontaneously developed near-total resistance to Tamiflu. Swine H1N1 could well do the same, particularly if it starts swapping genes with the human virus. Our best hope might lie in monoclonal antibodies, which could both prevent infection and help fight it. These immune proteins can be engineered to recognise a specific virus, and then churned out in production plants. Several research groups have made monoclonal antibodies to H5N1 bird flu from the antibodies of survivors, and these have protected mice against H5N1. The same trick should work for swine flu - and once developed, large amounts could be produced in a matter of weeks. Several companies are already mass-producing flu monoclonals for ordinary H5N1, and could be switched to swine flu. Then there are treatments that help you survive flu symptoms rather than attacking the virus directly. Flu kills mainly by triggering a cytokine storm - runaway inflammation in the immune system. The steroids normally used to reduce inflammation don't work, because they also suppress the immune responses you need to fight the virus. Last year, researchers in Hong Kong reported that combining Relenza with two readily available non-steroidal anti-inflammatory drugs called COX-2 inhibitors helped save mice from H5N1. This year, US researchers had similar success with an experimental anti-inflammatory drug. Ultimately though, no one wants to catch a potentially lethal virus and it's pretty hard to hide from pandemic flu. That leaves vaccines. Right now these are made from killed or weakened flu viruses. But growing them takes time: New Scientist has seen part of a confidential report for the International Federation of Pharmaceutical Manufacturers and Associations which says that in the next four months we can make a billion doses of pandemic vaccine at best, but more probably 340 million doses. This is not nearly enough for the world's people. Very few countries have vaccine production plants, and people in those that don't could get little vaccine or none (see "How the world threw away the chance to defeat a pandemic"). Other kinds of vaccine could be cooked up much faster in more countries. DNA vaccines are loops of DNA coding for the surface genes of the flu virus. Once injected into the skin, these are taken up by immune cells and turned into proteins. In the process, the immune cells learn how to recognise and fight the viruses that usually express those proteins - and even slightly different ones that might emerge as a pandemic evolves. Peter Dunnill of University College London calculated in 2006 that the entire world could be vaccinated with a mere 150 kilograms of DNA vaccine, and called for a global task force to scale up production. It didn't happen. Meanwhile, several groups are looking for a universal vaccine that will work against all flu, once and for all. Several proteins common to all flu viruses show promise in animal and early human trials, and more were recently found that might prompt strong immune responses. Protein vaccines could be made in existing factories in the quantities needed. Under normal circumstances that wouldn't happen without years of testing - but circumstances may no longer be normal.www.newscientist.com/article/mg202270...
mr$ schreef:
Level 5 wordt zo aangekondigd.
Bron: Bloomberg
edition.cnn.com/2009/HEALTH/04/29/swi...
Alarmfase 5 wegens Mexicaanse griep 29 april 2009, 22:17 | ANP GENEVE (ANP) - De Wereldgezondheidsorganisatie WHO heeft woensdagavond de alarmfase voor de Mexicaanse griep verhoogd. Er is nu sprake van alarmfase 5, de laatste fase voordat gesproken kan worden over een pandemie. Dat maakte de voorzitter van de WHO bekend. Het verhogen van de alarmfase is vooral een signaal aan overheden en de farmaceutische industrie. Volgens de WHO moeten alle landen ter wereld zich klaarmaken voor de uitbraak van een pandemie.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
899,60
-0,05%
EUR/USD
1,0750
-0,06%
FTSE 100
8.354,05
+0,49%
Germany40^
18.507,80
+0,05%
Gold spot
2.310,09
+0,05%
NY-Nasdaq Composite
16.302,76
-0,18%
Stijgers
Dalers